Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - stephen+traynelis
12
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Small Molecule Compound to Treat Neurological Diseases
Application NMDAR agents for the treatment of various neurological diseases. Key Benefits Exemplary compound EU1180-490 is a potent and selective potentiator of GluN1/GluN3 NMDARs. The compound has excellent Lipinski drug-like properties including low molecular weight and cLogP, as well as water solubility. The initial studies have determined...
Published: 7/30/2024
|
Inventor(s):
Dennis Liotta
,
Stephen Traynelis
,
Hongjie Yuan
,
Matthew Epplin
,
Samantha Summer
,
David Menaldino
,
Leon Jacobs
,
Adam McCallum
Keywords(s):
Neuroscience/Pain
,
Small Molecule
Category(s):
TechPub Algolia > Drug Discovery
,
TechPub Algolia > Therapeutics
PMU-Embedded Analytics for Online Event Detection and Classification in Power Grids
The energy requirement of the world is increasing exponentially every year. With the power demand sites concentrated in the region with the highest population density, energy production sites must be located remotely. This isolation requires lengthy and complicated grids to be designed and manufactured to transmit power over long distances. Grid failures...
Published: 7/30/2024
|
Inventor(s):
Payman Dehghanian
,
Shiyuan Wang
,
Li Li
Keywords(s):
Category(s):
Technology Classifications > Industrial or Consumer Tech > Energy Infrastructure and Environment
Subunit-Selective NMDAR Antagonists for Treatment of Neurological Disorders
Application GluN2C/2D selective inhibitors that modulate N-methyl-D-aspartic acid receptors (NMDAR) in a subunit-selective manner for treatment of neurological disorders. Key Benefits Specifically targets NMDARs that contain the GluN2C/2D subunit. Higher potency and efficacy compared to previously reported GluN2C/2D-selective modulators. Market...
Published: 8/22/2024
|
Inventor(s):
Yao Jing
,
Stephen Traynelis
,
Dennis Liotta
Keywords(s):
Neuroscience/Pain
,
Small Molecule
Category(s):
TechPub Algolia > Therapeutics
,
TechPub Algolia > Drug Discovery
Subunit-Selective Modulator for Treatment of Neurological Disorders
Application Subunit-selective GluN2C and GluN2D positive allosteric modulators of N-methyl-D-aspartic acid receptors (NMDAR) for treatment of neurological disorders. Key Benefits Specifically targets GluN2C/D subunits for positive modulation of NMDAR activity. Higher potency compared to non-selective modulators. Improved drug-like properties...
Published: 7/30/2024
|
Inventor(s):
Matthew Epplin
,
David Menaldino
,
Stephen Traynelis
,
Dennis Liotta
Keywords(s):
Neuroscience/Pain
,
Small Molecule
Category(s):
TechPub Algolia > Drug Discovery
,
TechPub Algolia > Therapeutics
EasyOocyte: Software for Recording Digital Record from Xenopus Laevis Oocytes
ApplicationSoftware to automate drug application and data collection for recording from Xenopus oocytes.Key BenefitsEnables automation of pharmacological experiments.Improves the efficiency of research and pharmaceutical drug development.Technical SummaryEmory University researchers have developed software to increase the efficiency of electrophysiological...
Published: 7/30/2024
|
Inventor(s):
Stephen Traynelis
,
Kevin Ogden
Keywords(s):
Research Study Tools
Category(s):
TechPub Algolia > Software
,
TechPub Algolia > Research Tools
,
TechPub Algolia > Drug Discovery
Cre-Lox PAR1 Conditional Knockout Mouse
Key BenefitsTissue-specific knockout mouse, allowing PAR1 to be inactivated in specific cell types in certain tissue.Inducible knockout mouse, allowing PAR1 to be temporally suppressed at a given time-point in embryonic, post-natal or adult animals.Eliminates drawbacks and side effects of traditional knockout processes that eliminate genes from the...
Published: 7/30/2024
|
Inventor(s):
Stephen Traynelis
Keywords(s):
Animal Model
,
Cardiovascular
,
Neuroscience/Pain
,
Oncology
Category(s):
TechPub Algolia > Research Tools
Positive Allosteric Modulators that Treat Central Nervous System Disorders
Application Small molecules that selectively potentiate N-methyl-D-aspartate (NMDA) receptor subunits GluN2C/GluN2D for the treatment of neurological conditions. Key Benefits Selective potentiation of only NMDA receptor that contain GluN2C or GluN2D subunits will likely reduce adverse side effects. Selective potentiation of only NMDA receptor...
Published: 7/30/2024
|
Inventor(s):
Stephen Traynelis
,
Praseeda Mullasseril
Keywords(s):
Neuroscience/Pain
,
Small Molecule
Category(s):
TechPub Algolia > Therapeutics
Small Molecule Potentiators for Treatment of Central Nervous System Disorders
Application Series of compounds for selectively potentiating N-methyl-D-aspartate (NMDA) receptor subunit NR2C for treating central nervous system impairment. Key Benefits Selectivity for NR2C may reduce possibility of adverse side effects. Market Summary N-methyl-D-aspartate (NMDA) receptors are widely dispersed in the central nervous system...
Published: 7/30/2024
|
Inventor(s):
Stephen Traynelis
,
Praseeda Mullasseril
,
Ethel Garnier-Amblard
,
Dennis Liotta
,
Sommer Zimmerman
Keywords(s):
Neuroscience/Pain
,
Small Molecule
Category(s):
TechPub Algolia > Therapeutics
,
TechPub Algolia > Drug Discovery
Small Molecule Potentiators of NMDA Receptors for Treating Neurological Conditions
Application Multiple series of small molecules that selectivity potentiate NMDA receptors composed of specific subunits including GluN2B, GluN2C, GluN2B/GluN2C/GluN2D, and GluN2C/GluN2D. Key Benefits Small molecule potentiators enhance endogenous signals without exogenous activation. Subunit selectivity allows targeting of specific subtypes of...
Published: 7/30/2024
|
Inventor(s):
Dennis Liotta
,
Ethel Garnier-Amblard
,
Gabriela Fernandez-Cuervo
,
Lanny Liebeskind
,
Pavan Kumar Reddy Gangireddy
,
Stephen Traynelis
,
Katie Strong
,
Rose Santangelo-Freel
Keywords(s):
Neuroscience/Pain
,
Small Molecule
Category(s):
TechPub Algolia > Drug Discovery
,
TechPub Algolia > Therapeutics
GluN2C/D-selective Antagonists for Treatment of Neurological Disorders
Application A new series of compounds for selectively inhibiting N-methyl-D-aspartate (NMDA) receptor subunits for the treatment of Parkinson's disease, schizophrenia, treatment-resistant depression, and ischemia. Key Benefits Improved anatomical selectivity in NMDA receptor modulation may result in fewer adverse side effects. Targeted antagonism...
Published: 8/22/2024
|
Inventor(s):
Timothy Acker
,
Stephen Traynelis
,
Dennis Liotta
Keywords(s):
Neuroscience/Pain
,
Small Molecule
Category(s):
TechPub Algolia > Therapeutics
1
2